• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups.差异很重要：不同种族群体的乳腺癌治疗
J Glob Oncol. 2017 Apr 11;3(4):281-284. doi: 10.1200/JGO.2017.009936. eCollection 2017 Aug.
2
Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968-2002.1968 - 2002年新加坡女性乳腺癌发病率时间趋势的种族差异
BMC Cancer. 2006 Nov 2;6:261. doi: 10.1186/1471-2407-6-261.
3
Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?新西兰乳腺癌生存的种族差异：哪些因素起作用？
BMC Cancer. 2018 Jan 8;18(1):58. doi: 10.1186/s12885-017-3797-0.
4
A cohort study of ethnic differences in use of adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand.新西兰乳腺癌辅助化疗和放疗使用情况种族差异的队列研究。
BMC Health Serv Res. 2017 Jan 21;17(1):64. doi: 10.1186/s12913-017-2027-4.
5
Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study.新西兰乳腺癌辅助化疗和放疗及时性方面的种族差异：一项队列研究。
BMC Cancer. 2014 Nov 18;14:839. doi: 10.1186/1471-2407-14-839.
6
Evaluation of a pilot study for breast and cervical cancer screening with Bradford's minority ethnic women; a community development approach, 1991-93.对1991 - 1993年针对布拉德福德少数族裔女性进行乳腺癌和宫颈癌筛查的一项试点研究的评估；一种社区发展方法
Br J Cancer Suppl. 1996 Sep;29:S42-6.
7
Breast health information needs of women from minority ethnic groups.少数族裔女性的乳房健康信息需求
J Adv Nurs. 2004 Sep;47(5):526-35. doi: 10.1111/j.1365-2648.2004.03125.x.
8
Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities.四种不同族裔乳腺癌中 microRNAs 的差异表达。
Pathobiology. 2018;85(4):220-226. doi: 10.1159/000488456. Epub 2018 May 23.
9
Ethnicity differences in breast cancer stage at the time of diagnosis in Norway.挪威乳腺癌诊断时的种族差异。
Scand J Surg. 2015 Dec;104(4):248-53. doi: 10.1177/1457496914565420. Epub 2015 Feb 27.
10
The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality.
Breast Cancer Res Treat. 2004 Dec;88(3):281-5. doi: 10.1007/s10549-004-0726-0.

引用本文的文献

1
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.日本人群与日裔及其他族裔美国人群的乳腺癌生存情况：一项基于注册的比较研究。
Breast Cancer Res Treat. 2020 Nov;184(2):585-596. doi: 10.1007/s10549-020-05869-y. Epub 2020 Aug 20.
2
Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.在绝经后早期乳腺癌女性中，甾体类芳香化酶抑制剂比非甾体类芳香化酶抑制剂对血脂谱有更有利的影响：一项前瞻性队列研究。
Ther Adv Med Oncol. 2020 May 26;12:1758835920925991. doi: 10.1177/1758835920925991. eCollection 2020.
3
CDK4/6 inhibitors in advanced breast cancer, what is beyond?晚期乳腺癌中的CDK4/6抑制剂，未来何去何从？
Oncol Rev. 2019 Jul 29;13(2):416. doi: 10.4081/oncol.2019.416. eCollection 2019 Jul 22.
4
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.基于模型的纳武利尤单抗在中国经治晚期实体瘤患者（包括非小细胞肺癌）中的群体药代动力学分析。
J Clin Pharmacol. 2019 Oct;59(10):1415-1424. doi: 10.1002/jcph.1432. Epub 2019 May 22.
5
More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens.不只是为了寻找治疗方法：高通量癌细胞系筛选的前景与挑战。
Pharmacol Ther. 2018 Nov;191:178-189. doi: 10.1016/j.pharmthera.2018.06.014. Epub 2018 Jun 25.

本文引用的文献

1
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.PALOMA-3：在既往内分泌治疗后进展的激素受体阳性、人表皮生长因子受体2阴性的绝经前和绝经后转移性乳腺癌患者中，来曲唑联合或不联合帕博西尼的III期试验——亚洲患者的安全性和疗效
J Glob Oncol. 2017 Apr 11;3(4):289-303. doi: 10.1200/JGO.2016.008318. eCollection 2017 Aug.
2
Palbociclib and Letrozole in Advanced Breast Cancer.帕博西尼联合来曲唑治疗晚期乳腺癌。
N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.
3
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.瑞博西尼作为激素受体阳性晚期乳腺癌的一线治疗方案
N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.
4
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.帕博西尼联合来曲唑作为雌激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌一线治疗的疗效和安全性：随机关键试验PALOMA-1/TRIO-18亚组的扩展分析
Breast Cancer Res. 2016 Jun 28;18(1):67. doi: 10.1186/s13058-016-0721-5.
5
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.体重指数与氟维司群对绝经后晚期乳腺癌女性的临床获益
Tumori. 2016 Aug 3;102(4):e11-4. doi: 10.5301/tj.5000515.
6
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.细胞周期蛋白依赖性激酶4/6抑制剂帕博西尼在日本患者中的I期研究。
Cancer Sci. 2016 Jun;107(6):755-63. doi: 10.1111/cas.12932. Epub 2016 May 11.
7
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.氟维司群联合帕博西尼对比氟维司群联合安慰剂治疗既往内分泌治疗进展的激素受体阳性、HER2 阴性转移性乳腺癌（PALOMA-3）：多中心、双盲、III 期随机对照临床试验的最终分析。
Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.
8
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.帕博西尼治疗激素受体阳性晚期乳腺癌。
N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.
10
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.帕妥珠单抗联合曲妥珠单抗和多西他赛在亚洲人表皮生长因子受体 2 阳性转移性乳腺癌患者中的安全性特征：来自 III 期 CLEOPATRA 试验的结果。
Oncologist. 2014 Jul;19(7):693-701. doi: 10.1634/theoncologist.2014-0033. Epub 2014 May 28.

Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups.

作者信息

Costa Ricardo L B, Gradishar William J

机构信息

Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

出版信息

J Glob Oncol. 2017 Apr 11;3(4):281-284. doi: 10.1200/JGO.2017.009936. eCollection 2017 Aug.

DOI:10.1200/JGO.2017.009936
PMID:28831435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5560466/
Abstract
摘要